PPAR promotes growth and invasion of thyroid cancer cells

PPAR Research

Volumn , Issue , 2011, Pages

  Wood, William M ^a,b   Sharma, Vibha ^a   Bauerle, Kevin T ^a   Pike, Laura A ^a   Zhou, Qiong ^a   Fretwell, Deborah L ^a   Schweppe, Rebecca E ^a,b   Haugen, Bryan R ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INVASION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; THYROID CANCER; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84855573044     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2011/171765     Document Type: Article

References (41)

1. Willson T. M., Brown P. J., Sternbach D. D., Henke B. R., The PPARs: from orphan receptors to drug discovery Journal of Medicinal Chemistry 2000 43 4 527 550 (Pubitemid 30127149)
2. Wahli W., Braissant O., Desvergne B., Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more Chemistry and Biology 1995 2 5 261 266
3. Grimaldi P. A., The roles of PPARs in adipocyte differentiation Progress in Lipid Research 2001 40 4 269 281 (Pubitemid 32544959)
4. Tontonoz P., Singer S., Forman B. M., Sarraf P., Fletcher J. A., Fletcher C. D. M., Brun R. P., Mueller E., Altiok S., Oppenheim H., Evans R. M., Spiegelman B. M., Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor and the retinoid X receptor Proceedings of the National Academy of Sciences of the United States of America 1997 94 1 237 241 (Pubitemid 27027193)
5. Sarraf P., Mueller E., Jones D., King F. J., DeAngelo D. J., Partridge J. B., Holden S. A., Chen L. B., Singer S., Fletcher C., Spiegelman B. M., Differentiation and reversal of malignant changes in colon cancer through PPAR Nature Medicine 1998 4 9 1046 1052 (Pubitemid 28417337)
6. Bren-Mattison Y., Van Putten V., Chan D., Winn R., Geraci M. W., Nemenoff R. A., Peroxisome proliferator-activated receptor- (PPAR ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC) Oncogene 2005 24 8 1412 1422 (Pubitemid 40343121)
7. Keshamouni V. G., Reddy R. C., Arenberg D. A., Joel B., Thannickal V. J., Kalemkerian G. P., Standiford T. J., Peroxisome proliferator-activated receptor- activation inhibits tumor progression in non-small-cell lung cancer Oncogene 2004 23 1 100 108 (Pubitemid 38142244)
8. Seed B., PPAR and colorectal carcinoma: conflicts in a nuclear family Nature Medicine 1998 4 9 1004 1005 (Pubitemid 28417325)
9. Abe A., Kiriyama Y., Hirano M., Miura T., Kamiya H., Harashima H., Tokumitsu Y., Troglitazone suppresses cell growth of KU812 cells independently of PPAR European Journal of Pharmacology 2002 436 1-2 7 13 (Pubitemid 34142392)
10. Wei S., Yang J., Lee S. L., Kulp S. K., Chen C. S., PPAR -independent antitumor effects of thiazolidinediones Cancer Letters 2009 276 2 119 124
11. Ohta K., Endo T., Haraguchi K., Hershman J. M., Onaya T., Ligands for peroxisome proliferator-activated receptor inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells Journal of Clinical Endocrinology and Metabolism 2001 86 5 2170 2177 (Pubitemid 32472935)
12. Martelli M. L., Iuliano R., Le Pera I., Sama' I., Monaco C., Cammarota S., Kroll T., Chiariotti L., Santoro M., Fusco A., Inhibitory effects of peroxisome proliferator-activated receptor on thyroid carcinoma cell growth Journal of Clinical Endocrinology and Metabolism 2002 87 10 4728 4735 (Pubitemid 35247068)
13. Park J. W., Zarnegar R., Kanauchi H., Wong M. G., Hyun W. C., Ginzinger D. G., Lobo M., Cotter P., Duh Q. Y., Clark O. H., Troglitazone, the peroxisome proliferator-activated receptor- agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines Thyroid 2005 15 3 222 231 (Pubitemid 40418689)
14. Aiello A., Pandini G., Frasca F., Conte E., Murabito A., Sacco A., Genua M., Vigneri R., Belfiore A., Peroxisomal proliferator-activated receptor- agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells Endocrinology 2006 147 9 4463 4475 (Pubitemid 44268398)
15. Copland J. A., Marlow L. A., Kurakata S., Fujiwara K., Wong A. K. C., Kreinest P. A., Williams S. F., Haugen B. R., Klopper J. P., Smallridge R. C., Novel high-affinity PPAR agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1 Oncogene 2006 25 16 2304 2317
16. Schweppe R. E., Klopper J. P., Korch C., Pugazhenthi U., Benezra M., Knauf J. A., Fagin J. A., Marlow L. A., Copland J. A., Smallridge R. C., Haugen B. R., Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification Journal of Clinical Endocrinology and Metabolism 2008 93 11 4331 4341 (Pubitemid 352789529)
17. Klopper J. P., Sharma V., Berenz A., Hays W. R., Loi M., Pugazhenthi U., Said S., Haugen B. R., Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression Molecular Cancer 2009 8, article 16
18. Klopper J. P., Berenz A., Hays W. R., Sharma V., Pugazhenthi U., Janssen J., Singh M., Bissonnette R. P., Haugen B. R., In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma Clinical Cancer Research 2008 14 2 589 596 (Pubitemid 351226129)
19. Kebebew E., Peng M., Reiff E., Treseler P., Woeber K. A., Clark O. H., Greenspan F. S., Lindsay S., Duh Q. Y., Morita E., A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer Surgery 2006 140 6 960 966
20. Philips J. C., Petite C., Willi J. P., Buchegger F., Meier C. A., Effect of peroxisome proliferator-activated receptor agonist, rosiglitazone, on dedifferentiated thyroid cancers Nuclear Medicine Communications 2004 25 12 1183 1186 (Pubitemid 39614279)
21. Marlow L. A., Reynolds L. A., Cleland A. S., Cooper S. J., Gumz M. L., Kurakata S., Fujiwara K., Zhang Y., Sebo T., Grant C., McIver B., Wadsworth J. T., Radisky D. C., Smallridge R. C., Copland J. A., Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth Cancer Research 2009 69 4 1536 1544
22. Ain K. B., Management of undifferentiated thyroid cancer Baillieres Best Practice and Research: Clinical Endocrinology and Metabolism 2000 14 4 615 629 (Pubitemid 32293858)
23. Nikiforova M. N., Biddinger P. W., Caudill C. M., Kroll T. G., Nikiforov Y. E., PAX8-PPAR rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses The American Journal of Surgical Pathology 2002 26 8 1016 1023 (Pubitemid 34810562)
24. Aldred M. A., Morrison C., Gimm O., Hoang-Vu C., Krause U., Dralle H., Jhiang S., Eng C., Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas Oncogene 2003 22 22 3412 3416 (Pubitemid 36713738)
25. Karger S., Berger K., Eszlinger M., Tannapfel A., Dralle H., Paschke R., Fhrer D., Evaluation of peroxisome proliferator-activated receptor- expression in benign and malignant thyroid pathologies Thyroid 2005 15 9 997 1003 (Pubitemid 41475709)
26. Hayashi N., Nakamori S., Hiraoka N., Tsujie M., Xundi X., Takano T., Amino N., Sakon M., Monden M., Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma International Journal of Oncology 2004 24 1 89 95
27. Yu J., Shen B., Chu E. S. H., Teoh N., Cheung K. F., Wu C. W., Wang S., Lam C. N. Y., Feng H., Zhao J., Cheng A. S. L., To K. F., Chan H. L. Y., Sung J. J. Y., Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro Hepatology 2010 51 6 2008 2019
28. McAlpine C. A., Barak Y., Matise I., Cormier R. T., Intestinal-specific PPAR deficiency enhances tumorigenesis in ApcMin/+ mice International Journal of Cancer 2006 119 10 2339 2346 (Pubitemid 44546953)
29. Kato Y., Ying H., Zhao L., Furuya F., Araki O., Willingham M. C., Cheng S. Y., PPAR insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor- B signaling pathway Oncogene 2006 25 19 2736 2747
30. Saez E., Rosenfeld J., Livolsi A., Olson P., Lombardo E., Nelson M., Banayo E., Cardiff R. D., Izpisua-Belmonte J. C., Evans R. M., PPAR signaling exacerbates mammary gland tumor development Genes and Development 2004 18 5 528 540 (Pubitemid 38372810)
31. Reddi H. V., Madde P., Milosevic D., Hackbarth J. S., Algeciras-Schimnich A., Mciver B., Grebe S. K.G., Eberhardt N. L., The putative PAX8/PPAR fusion oncoprotein exhibits partial tumor suppressor activity through Up-regulation of Micro-RNA-122 and dominant-negative PPAR activity Genes Cancer 2011 2 1 46 55
32. Yam C. H., Fung T. K., Poon R. Y. C., Cyclin A in cell cycle control and cancer Cellular and Molecular Life Sciences 2002 59 8 1317 1326
33. Kawamoto H., Koizumi H., Uchikoshi T., Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses The American Journal of Pathology 1997 150 1 15 23 (Pubitemid 27027091)
34. Chung S. H., Onoda N., Ishikawa T., Ogisawa K., Takenaka C., Yano Y., Hato F., Hirakawa K., Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells Japanese Journal of Cancer Research 2002 93 12 1358 1365 (Pubitemid 36104876)
35. Bonofiglio D., Qi H., Gabriele S., Catalano S., Aquila S., Belmonte M., And S., Peroxisome proliterator-activated receptor inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner Endocrine-Related Cancer 2008 15 2 545 557 (Pubitemid 351880842)
36. Fajas L., Egler V., Reiter R., Miard S., Lefebvre A. M., Auwerx J., PPAR controls cell proliferation and apoptosis in an RB-dependent manner Oncogene 2003 22 27 4186 4193 (Pubitemid 36876239)
37. Morrison R. F., Farmer S. R., Role of PPAR in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18INK4c and p21Waf1/Cip1, during adipogenesis Journal of Biological Chemistry 1999 274 24 17088 17097
38. Itami A., Watanabe G., Shimada Y., Hashimoto Y., Kawamura J., Kato M., Hosotani R., Imamura M., Ligands for peroxisome proliferator-activated receptor inhibit growth of pancreatic cancers both in vitro and in vivo International Journal of Cancer 2001 94 3 370 376 (Pubitemid 32906067)
39. Liu H., Zang C., Fenner M. H., Possinger K., Elstner E., PPAR ligands and ATRA inhibit the invasion of human breast cancer cells in vitro Breast Cancer Research and Treatment 2003 79 1 63 74 (Pubitemid 36561044)
40. Yang Y. C., Ho T. C., Chen S. L., Lai H. Y., Wu J. W., Tsao Y. P., Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line BMC Cancer 2007 7, article 216
41. Coras R., Hlsken A., Seufert S., Hauke J., Eypoglu I. Y., Reichel M., Trnkle C., Siebzehnrbl F. A., Buslei R., Blmcke I., Hahnen E., The peroxisome proliferator-activated receptor- agonist troglitazone inhibits transforming growth factor- -mediated glioma cell migration and brain invasion Molecular Cancer Therapeutics 2007 6 6 1745 1754 (Pubitemid 46954051)